KidneyIntelX included in final KDIGO 2024 guideline for CKD risk prediction

Renalytix plc

KidneyIntelX recommended for predicting CKD progression in stages G1-G3 per KDIGO 2024 guideline released March 13.
FDA de-novo marketing authorization for kidneyintelX.dkd received June 2023 for use in type 2 diabetes patients.
Outcomes data from >2,500 patients showed sustained reduction in eGFR decline and improved diabetes/cardiovascular management.
Current enrollment >9,000 patients with type 2 diabetes and CKD for ongoing clinical utility and outcomes studies.
Guideline emphasizes risk prediction and personalized treatment; Renalytix aims to expand evidence base.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.